Beam Therapeutics (BEAM) Gains from Investment Securities (2019 - 2026)
Beam Therapeutics (BEAM) reported Gains from Investment Securities of $157669.0 for Q1 2026, up 161.65% year-over-year from $60259.0 in Q1 2025, and down 71.12% quarter-over-quarter from $546000.0 in Q4 2025.
Beam Therapeutics (BEAM) Gains from Investment Securities (2019 - 2026) Analysis & Trends
Beam Therapeutics (BEAM) has 8 years of Gains from Investment Securities data on file, last reported at $157669.0 in Q1 2026.
- Gains from Investment Securities for Q1 2026 came in at $157669.0, up 161.65% year-over-year; the trailing twelve-month figure through Mar 2026 was $157669.0 (up 161.65% YoY), and the FY2025 annual result was $11.3 million, up 17.81% from the prior year.
- Gains from Investment Securities fell to $157669.0 in Q1 2026 per BEAM's latest filing, from $546000.0 in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $30.8 million in Q2 2022 and troughed at -$1.6 million in Q4 2023.
- A 5-year average of $4.5 million and a median of $531231.5 in 2025 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2022 and 2025: Gains from Investment Securities soared 94015.67% in 2022, then plunged 99.4% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $250000.0 in 2022, then plunged by 748.0% to -$1.6 million in 2023, then jumped by 229.88% to $2.1 million in 2024, then tumbled by 74.05% to $546000.0 in 2025, then tumbled by 71.12% to $157669.0 in 2026.
- Business Quant data shows BEAM's Gains from Investment Securities at $157669.0 in Q1 2026, $546000.0 in Q4 2025, and $516463.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Beam Therapeutics | 3.53 Bn | 3.53 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 157,669.00 |
| Mar 31, 2026 | 157,669.00 |
| Dec 31, 2025 | 546,000.00 |
| Dec 31, 2025 | 546,000.00 |
| Sep 30, 2025 | 516,463.00 |
| Sep 30, 2025 | 516,463.00 |
| Jun 30, 2025 | 320,607.00 |
| Jun 30, 2025 | 320,607.00 |
| Mar 31, 2025 | 60,259.00 |
| Mar 31, 2025 | 60,259.00 |
| Dec 31, 2024 | 2.10 Mn |
| Dec 31, 2024 | 2.10 Mn |
| Sep 30, 2024 | 27,000.00 |
| Sep 30, 2024 | 27,000.00 |
| Jun 30, 2024 | 10.14 Mn |
| Jun 30, 2024 | 10.14 Mn |
| Mar 31, 2024 | 9.97 Mn |
| Mar 31, 2024 | 9.97 Mn |
| Dec 31, 2023 | -1.62 Mn |
| Dec 31, 2023 | -1.62 Mn |